Marksans Pharma
Ticker > Company >

Marksans Pharma share price

Marksans Pharma Ltd.

NSE: MARKSANS BSE: 524404 SECTOR: Pharmaceuticals & Drugs  2.9 L   1.63 K   297

176.00
+3.05 (1.76%)
BSE: Today, 09:05 AM

Price Summary

Today's High

₹ 0

Today's Low

₹ 0

52 Week High

₹ 358.5

52 Week Low

₹ 165.45

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 7975.68 Cr.

Enterprise Value

₹ 7706.99 Cr.

No. of Shares

45.32 Cr.

P/E

39.04

P/B

5.57

Face Value

₹ 1

Div. Yield

0.46 %

Book Value (TTM)

₹  31.59

CASH

₹ 268.69 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

43.87 %

EPS (TTM)

₹  4.51

Sales Growth

37.63%

ROE

14.45 %

ROCE

18.76%

Profit Growth

40.76 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Marksans Pharma Ltd.

RelonChem Time-Caps labs Bell's Healthcare NOVA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year37.63%
3 Year21.28%
5 Year22.06%

Profit Growth

1 Year40.76%
3 Year21.88%
5 Year37.79%

ROE%

1 Year14.45%
3 Year12.44%
5 Year14.25%

ROCE %

1 Year18.76%
3 Year15.95%
5 Year18.24%

Debt/Equity

0

Price to Cash Flow

257.13

Interest Cover Ratio

208.2053

CFO/PAT (5 Yr. Avg.)

0.445881724629941

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 43.87 0.00
Mar 2025 43.87 0.00
Dec 2024 43.87 0.00
Sep 2024 43.87 0.00
Jun 2024 43.87 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 21.8804840053182% for the Past 3 years.
  • The company has shown a good revenue growth of 21.281838531436% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 208.2053.
  • Company’s PEG ratio is 0.957885298848671.
  • Company has a healthy liquidity position with current ratio of 2.9058.

 Limitations

  • The company is trading at a high PE of 39.04.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 254.53 308.63 311.87 299.36 319.73
Total Expenditure 213.26 256.35 251.93 248.78 249.68
Operating Profit 41.27 52.27 59.94 50.57 70.05
Other Income 8.15 31.36 22.51 7.82 2.01
Interest 0.28 0.28 0.3 0.31 0.3
Depreciation 6.84 7.02 7.42 8.18 8.19
Exceptional Items 0 0 0 0 0
Profit Before Tax 42.3 76.34 74.72 49.9 63.57
Tax 10.28 13.13 19.26 12.31 15.52
Profit After Tax 32.02 63.2 55.46 37.59 48.06
Adjusted EPS (Rs) 0.71 1.39 1.22 0.83 1.06

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 599.55 658.29 655.2 853.27 1174.37
Total Expenditure 485.84 544.57 582.23 713.34 970.32
Operating Profit 113.71 113.72 72.97 139.94 204.05
Other Income 31.16 42.25 79.41 62.07 69.83
Interest 5.35 3.8 3.61 0.99 1.17
Depreciation 15.19 17.66 16.74 29.13 29.45
Exceptional Items 0 0 0 0 0
Profit Before Tax 124.33 134.51 132.04 171.89 243.26
Tax 25.95 30.52 29.17 38.13 54.99
Net Profit 98.38 103.99 102.87 133.76 188.27
Adjusted EPS (Rs.) 2.4 2.54 2.27 2.95 4.15

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 40.93 40.93 45.32 45.32 45.32
Total Reserves 558.79 743.74 1066.01 1177.39 1338.17
Borrowings 0 0 0 0 0
Other N/C liabilities 23.94 14.41 17 20.9 26.18
Current liabilities 137.26 190.39 240.91 304.73 386.49
Total Liabilities 760.91 989.47 1369.23 1548.33 1796.16
Assets
Net Block 129.09 135.51 143.94 271.58 383.37
Capital WIP 0 0 3.91 0 0
Intangible WIP 0 0 0 0 0
Investments 236.07 236.07 265.75 265.75 265.75
Loans & Advances 4.16 4.16 17.5 30.84 23.79
Other N/C Assets 0 0 0 0.17 0.17
Current Assets 391.6 613.73 938.13 979.99 1123.08
Total Assets 760.91 989.47 1369.23 1548.33 1796.16
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 124.33 134.51 132.04 171.89 243.26
Adjustment -8.82 -7.93 10.91 -16.4 -7.59
Changes in Assets & Liabilities 11.62 -38.77 -59.6 -82.68 -158.11
Tax Paid -20.21 -31.83 -31.62 -38.76 -46.54
Operating Cash Flow 106.92 55.97 51.73 34.05 31.02
Investing Cash Flow 8.87 -128.06 -194.62 -114.22 17.24
Financing Cash Flow -13.53 70.86 210.02 -26.22 -29.92
Net Cash Flow 102.26 -1.23 67.12 -106.38 18.34

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 43.87 43.87 43.87 43.87 43.87
mark saldanha 43.80 43.80 43.80 43.80 43.80
sandra saldanha 0.07 0.07 0.07 0.07 0.07
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 56.13 56.13 56.13 56.13 56.13
investor education and pr... 0.15 - - - 0.18
kotak mahindra trustee co... - - - 1.05 1.10
massachusetts institute o... 2.32 2.32 2.32 2.32 2.32
orbimed asia iv mauritius... 10.88 10.88 10.88 10.88 8.62
uti-healthcare fund - - - 1.41 1.37
investor education and pr... - 0.15 0.18 0.18 -
uti small cap fund 2.05 1.51 1.30 - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INDIA RATINGS
Credit CARE
Credit CARE
Credit CARE
Credit FITCH
Credit CARE
Credit FITCH
Credit FITCH
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
Research Ventura
Research Ventura
Research HDFC Securities
Research Ventura
Research BP Wealth
Research HDFC Securities
Research HDFC Securities
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY23
Concall Q3FY25
Concall Q3FY24
Concall Q3FY23
Concall Q2FY23
Concall Q2 FY25
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21

Company News

Marksans Pharma informs about updates 25 Aug, 3:19 PM Marksans Pharma informs about analyst meet 19 Aug, 2:50 PM Marksans Pharma’s arm receives marketing authorization from UK MHRA 18 Aug, 2:25 PM Marksans Pharma - Quaterly Results 12 Aug, 1:46 PM Marksans Pharma - Quaterly Results 12 Aug, 1:46 PM Marksans Pharma - Quaterly Results 12 Aug, 1:46 PM Marksans Pharma informs about disclosure 8 Aug, 2:46 PM Marksans Pharma’s arm gets approval from USFDA for Omeprazole Delayed-Release Tablets 8 Aug, 12:41 PM Marksans Pharma informs about newspaper publication 17 Jul, 2:46 PM Marksans Pharma informs about AGM 16 Jul, 4:56 PM Marksans Pharma’s arm gets EIR from USFDA for New York facility 30 Jun, 4:12 PM Marksans Pharma informs about trading window closure 25 Jun, 5:25 PM Marksans Pharma’s arm gets marketing authorization for Oxybutynin hydrochloride 19 Jun, 10:41 AM Marksans Pharma informs about updates 19 Jun, 9:58 AM Marksans Pharma informs about disclosure 30 May, 12:34 PM Marksans Pharma’s arm gets marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution 30 May, 10:41 AM Marksans Pharma reports 17% rise in Q4 consolidated net profit 20 May, 3:19 PM Marksans Pharma - Quaterly Results 19 May, 8:03 PM Marksans Pharma - Quaterly Results 19 May, 8:03 PM Marksans Pharma’s arm gets marketing authorization for Sennosides 7.5 mg Tablets 19 May, 4:09 PM Marksans Pharma’s arm receives marketing authorization for Gabapentin 15 May, 11:00 AM Marksans Pharma informs about press release 15 May, 10:13 AM Marksans Pharma informs about board meeting 8 May, 5:29 PM Marksans Pharma informs about board meeting 8 May, 12:03 PM USFDA completes cGMP inspection at manufacturing facility of Marksans Pharma’s arm 28 Apr, 12:40 PM Marksans Pharma informs about analyst meet 21 Mar, 4:35 PM Marksans Pharma’s Goa facility gets Australian TGA’s nod to manufacture pharmaceutical formulations 20 Mar, 2:51 PM Marksans Pharma informs about press release 20 Mar, 2:45 PM Marksans Pharma’s arm receives marketing authorization for Baclofen 19 Mar, 4:40 PM Marksans Pharma informs about press release 19 Mar, 2:58 PM Marksans Pharma informs about press release 25 Feb, 1:04 PM Marksans Pharma’s arm receives marketing authorization 25 Feb, 1:00 PM Marksans Pharma reports 27% rise in Q3 consolidated net profit 12 Feb, 11:10 AM Marksans Pharma - Quaterly Results 11 Feb, 8:53 PM Marksans Pharma - Quaterly Results 11 Feb, 8:53 PM Marksans Pharma informs about board meeting 22 Jan, 5:01 PM Marksans Pharma informs about certificate 8 Jan, 5:06 PM Marksans Pharma informs about trading window closure 30 Dec, 2:53 PM Marksans Pharma informs about transcript of earnings call 25 Nov, 12:49 PM Marksans Pharma gets USFDA’s final approval for Loratadine Tablets 23 Nov, 2:47 PM Marksans Pharma - Quaterly Results 12 Nov, 1:12 PM Marksans Pharma - Quaterly Results 12 Nov, 1:12 PM Marksans Pharma - Quaterly Results 12 Nov, 1:12 PM Marksans Pharma informs about loss of share certificate 5 Nov, 12:53 PM Marksans Pharma informs about newspaper advertisement 4 Sep, 12:48 PM Marksans Pharma informs about press release 21 Aug, 1:15 PM Marksans Pharma’s arm secures marketing authorization for three products 21 Aug, 12:11 PM USFDA issues EIR for Marksans Pharma’s Goa manufacturing facility 20 Aug, 3:59 PM Marksans Pharma - Quaterly Results 13 Aug, 7:55 PM Marksans Pharma - Quaterly Results 13 Aug, 7:55 PM

Marksans Pharma Stock Price Analysis and Quick Research Report. Is Marksans Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Marksans Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Marksans Pharma has a PE ratio of 38.3755489508938 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Marksans Pharma has ROA of 11.2587% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Marksans Pharma has a Current ratio of 2.9058.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Marksans Pharma has a ROE of 14.4481%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Marksans Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Marksans Pharma has reported revenue growth of 37.6317% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Marksans Pharma for the current financial year is 17.3752995212769%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Marksans Pharma is Rs 0.8 and the yield is 0.4634%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Marksans Pharma is Rs 4.5086. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Marksans Pharma in Ticker for free. Also, one can get the intrinsic value of Marksans Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Marksans Pharma FAQs

Q1. What is Marksans Pharma share price today?
Ans: The current share price of Marksans Pharma is Rs 173.02.

Q2. What is the market capitalisation of Marksans Pharma?
Ans: Marksans Pharma has a market capitalisation of Rs 7840.639133292 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Marksans Pharma?
Ans: The PE ratio of Marksans Pharma is 38.3755489508938 and the P/B ratio of Marksans Pharma is 5.47704969927192, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Marksans Pharma share?
Ans: The 52-week high share price of Marksans Pharma is Rs 358.7, and the 52-week low share price of Marksans Pharma is Rs 165.52.

Q5. Does Marksans Pharma pay dividends?
Ans: Currently, Marksans Pharma pays dividends. Dividend yield of Marksans Pharma is around 0.4634%.

Q6. What are the face value and book value of Marksans Pharma shares?
Ans: The face value of Marksans Pharma shares is Rs 1, while the book value per share of Marksans Pharma is around Rs 31.59. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Marksans Pharma?
Ans: Marksans Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Marksans Pharma?
Ans: The ROE of Marksans Pharma is 14.4481% and ROCE of Marksans Pharma is 18.7579%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Marksans Pharma a good buy for the long term?
Ans: The Marksans Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Marksans Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Marksans Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Marksans Pharma’s financials?
Ans: You can review Marksans Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Marksans Pharma

Marksans Pharma  Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Marksans Pharma Ltd. is a leading Indian pharmaceutical company with a global footprint. The company specializes in developing and manufacturing high-quality generic and branded pharmaceuticals, including active pharmaceutical ingredients (APIs), solid oral dosage forms, liquid dosage forms, and sterile dosage forms. The company is headquartered in Mumbai, India, and has operations in more than 60 countries worldwide.

Marksans Pharma Ltd. Share Price

The share price of Marksans Pharma Ltd. is an important metric for investors to track. The price of a share reflects the market's perception of the company's prospects, and can be influenced by a wide range of factors, including economic conditions, company-specific news, and industry trends. Investors can monitor the share price of Marksans Pharma Ltd. on our website, where we offer real-time quotes and charting tools.

Marksans Pharma Ltd. Balance Sheet

The balance sheet of Marksans Pharma Ltd. provides investors with a snapshot of the company's financial health. The balance sheet shows the company's assets, liabilities, and equity at a particular point in time, and can be used to assess the company's ability to meet its obligations and fund its growth. On our website, investors can access the balance sheet of Marksans Pharma Ltd. and use our pre-built screening tools and premium fair value calculation tools, including the DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis.

Marksans Pharma Ltd. Annual Report

The annual report of Marksans Pharma Ltd. is an important source of information for investors. The report provides details on the company's operations, financial performance, and strategy, and can be used to assess the company's prospects for growth and profitability. Investors can download the annual report of Marksans Pharma Ltd. from our website, along with other key documents such as concall transcripts, investor presentations, credit ratings, and research reports.

Marksans Pharma Ltd. Dividend

Marksans Pharma Ltd. has a track record of paying dividends to its shareholders. Dividends are a portion of the company's profits that are paid out to shareholders as a reward for their investment. Investors can track the dividends paid by Marksans Pharma Ltd. on our website, along with other key financial metrics such as earnings per share and return on equity.

Marksans Pharma Ltd. Quarterly Result

The quarterly results of Marksans Pharma Ltd. provide investors with an update on the company's financial performance over a three-month period. These results can be used to track the company's progress towards achieving its financial targets and to identify trends in its business operations. On our website, investors can access the quarterly results of Marksans Pharma Ltd. and use our premium fair value calculation tools to assess the company's financial health and prospects for growth.

Marksans Pharma Ltd. Stock Price

The stock price of Marksans Pharma Ltd. is determined by the supply and demand for the company's shares on the stock market. Investors can track the stock price of Marksans Pharma Ltd. on our website, using our real-time quotes and charting tools. The stock price is an important indicator of the market's perception of the company's prospects, and can be influenced by a wide range of factors, including economic conditions, company-specific news, and industry trends.

Marksans Pharma Ltd. Price Chart

The price chart of Marksans Pharma Ltd. provides investors with a visual representation of the company's stock price over time. This chart can be used to identify trends in the stock price and to assess the company's performance relative to its peers and the broader stock market. On our website, investors can access the price chart of Marksans Pharma Ltd. and use our charting tools to customize the display and analyze the data.

Marksans Pharma Ltd. News

Keeping up with the latest news and events related to Marksans Pharma Ltd. is an important part of stock analysis. Investors can access the latest news and press releases related to Marksans Pharma Ltd. on our website, as well as other sources of news and commentary from around the web. Our news aggregator pulls together news headlines, articles, and blogs related to the company, making it easy for investors to stay up-to-date with the latest developments.

Marksans Pharma Ltd. Concall Transcripts

Concall transcripts provide investors with a detailed record of the company's conference calls with analysts and investors. These transcripts can provide insight into the company's strategy, operations, and prospects, and can be used to identify trends and risks that may impact the company's stock price. On our website, investors can access concall transcripts for Marksans Pharma Ltd. and use our premium fair value calculation tools to assess the company's performance and prospects.

Marksans Pharma Ltd. Investor Presentations

Investor presentations are an important source of information for investors, providing an overview of the company's strategy, operations, and financial performance. On our website, investors can access investor presentations for Marksans Pharma Ltd. and use our premium fair value calculation tools to assess the company's prospects for growth and profitability.

Marksans Pharma Ltd. Promoters

The promoters of Marksans Pharma Ltd. are a group of individuals or entities who hold a significant stake in the company and have a vested interest in its success. Understanding the motives and actions of the promoters can provide insight into the company's prospects and risks. On our website, investors can access information about the promoters of Marksans Pharma Ltd. and use our screening tools and premium fair value calculation tools to analyze their impact on the company.

Marksans Pharma Ltd. Shareholders

The shareholders of Marksans Pharma Ltd. play an important role in the company's governance and decision-making process. Understanding the composition and actions of the shareholder base can provide insight into the company's prospects and risks. On our website, investors can access information about the shareholders of Marksans Pharma Ltd. and use our screening tools and premium fair value calculation tools to analyze their impact on the company.

Overall, Marksans Pharma Ltd. is a leading Indian pharmaceutical company with a global footprint. Investors seeking to analyze the company's stock should consider a wide range of factors, including its financial performance, strategy, industry trends, and market conditions. By accessing key information and analysis on our website, investors can stay ahead of the curve and make informed decisions about their investments. 

Marksans Pharma Equity and Liabilities Overview

The balance sheet of Marksans Pharma shows a steady growth in its equity and liabilities from March 2020 to March 2024. The share capital has seen an increase from Rs 40.93 Cr in March 2020 to Rs 45.32 Cr by March 2023, maintaining stability onwards. Particularly noteworthy is the total reserves, escalating from Rs 464.69 Cr in March 2020 to a significant Rs 1,177.39 Cr by March 2024. Interestingly, the company has maintained its borrowings at zero throughout the observed period, showcasing a debt-free status. The escalation in current liabilities from Rs 79.73 Cr to Rs 304.73 Cr indicates an expansion in operational activities.

Marksans Pharma Assets Growth

On the asset front, Marksans Pharma has demonstrated substantial growth. The net block has more than doubled from Rs 115.18 Cr in March 2020 to Rs 271.58 Cr by March 2024, reflecting significant capital expenditure into fixed assets. Investments remain stable at Rs 236.07 Cr, later increasing to Rs 265.75 Cr, showing prudent investment management. A notable increase in current assets from Rs 254.41 Cr to Rs 979.99 Cr underscores the company’s enhanced liquidity and operational efficiency.

This data represents an analysis for the Standalone Balance sheet of Marksans Pharma, illustrating its financial health and growth trajectory over the years. Investors and market analysts keeping an eye on NSE BSE indices may find Marksans Pharma a noteworthy entity given its performance and growth potential in its sector.

Read More
X